Mendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:*
*
*LSX Nordic Congress*
Copenhagen, Denmark, October 10-11, 2023
Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present a Company Update at the conference:
https://www.lsxleaders.com/lsx-nordic-congress
*
*
*Innate Killer Summit Europe*
London, UK, October 17-19, 2023
Mendus CTO Leopold Bertea will participate and present the Company at the conference:
https://innate-killer-europe.com/
*
*
*HealthTech** Innovation Days*
Paris, France, October 24-25, 2023
Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present a Company Update at the conference:
https://htfc-eu.com/htid/
Mendus also announced that data from the ongoing Phase 1 ALISON trial in ovarian cancer will be presented at the 38^th Society for the Immunotherapy of Cancer meeting (SITC 2023), to be held Nov. 1–5, 2023, at San Diego Convention Center in San Diego, USA. Full abstracts are expected to be published online on Oct. 31, 2023.
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
*
*
*FOR MORE INFORMATION, PLEASE CONTACT:*
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
INVESTOR RELATIONS
Corey Davis
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com
MEDIA RELATIONS
Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu
*Attachment*
· 230928_Mendus_Conferences_October_ENG